IBA Secures €35M–€45M Deal for Brazil’s First Proton Therapy Center
Event summary
- IBA has signed a €35M–€45M contract with FUSVE to install Brazil’s first proton therapy center in Rio de Janeiro, focused on pediatric cancer care.
- The Proteus®ONE system will be operational by H1 2030, with plans for a second treatment room in the future.
- This marks IBA’s second proton therapy center in Latin America, reinforcing its market leadership in advanced cancer treatment technology.
The big picture
IBA’s entry into Brazil with a high-value proton therapy system underscores the growing demand for advanced cancer treatment solutions in Latin America. The deal strengthens IBA’s position as the leading provider of such technology, particularly in pediatric care, while positioning FUSVE as a regional healthcare innovator. The €35M–€45M contract reflects the significant investment required to deploy cutting-edge medical infrastructure.
What we're watching
- Market Leadership
- Whether IBA can sustain its dominance in proton therapy as competition intensifies globally.
- Execution Risk
- The pace at which IBA and FUSVE deliver the project, given the 2030 timeline for patient treatment.
- Regional Expansion
- How this deal influences IBA’s strategy in other emerging markets beyond Latin America.
Related topics